-
1
-
-
79960088065
-
Physiological relevance of cell cycle kinases
-
Malumbres M. Physiological relevance of cell cycle kinases. Physiol Rev. 2011;91:973-1007.
-
(2011)
Physiol Rev
, vol.91
, pp. 973-1007
-
-
Malumbres, M.1
-
2
-
-
60749109846
-
Cell cycle, CDKs and cancer: A changing paradigm
-
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153-66.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 153-166
-
-
Malumbres, M.1
Barbacid, M.2
-
4
-
-
67650073265
-
Cell cycle kinases as therapeutic targets for cancer
-
Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009;8:547-66.
-
(2009)
Nat Rev Drug Discov
, vol.8
, pp. 547-566
-
-
Lapenna, S.1
Giordano, A.2
-
5
-
-
67650777303
-
Development of cellcycle inhibitors for cancer therapy
-
Dickson MA, Schwartz GK. Development of cellcycle inhibitors for cancer therapy. Curr Oncol. 2009;16:36-43.
-
(2009)
Curr Oncol
, vol.16
, pp. 36-43
-
-
Dickson, M.A.1
Schwartz, G.K.2
-
7
-
-
8644219655
-
Living with or without cyclins and cyclin-dependent kinases
-
Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18:2699-711.
-
(2004)
Genes Dev
, vol.18
, pp. 2699-2711
-
-
Sherr, C.J.1
Roberts, J.M.2
-
8
-
-
0029033861
-
The retinoblastoma protein and cell cycle control
-
Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323-30.
-
(1995)
Cell
, vol.81
, pp. 323-330
-
-
Weinberg, R.A.1
-
9
-
-
0032146274
-
The regulation of E2F by pRB-family proteins
-
Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 1998;12:2245-62.
-
(1998)
Genes Dev
, vol.12
, pp. 2245-2262
-
-
Dyson, N.1
-
10
-
-
33748047128
-
RB and cell cycle progression
-
Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25:5220-7.
-
(2006)
Oncogene
, vol.25
, pp. 5220-5227
-
-
Giacinti, C.1
Giordano, A.2
-
11
-
-
1942421702
-
Cyclin C/cdk3 promotes Rbdependent G0 exit
-
Ren S, Rollins BJ. Cyclin C/cdk3 promotes Rbdependent G0 exit. Cell. 2004;117:239-51.
-
(2004)
Cell
, vol.117
, pp. 239-251
-
-
Ren, S.1
Rollins, B.J.2
-
12
-
-
0028061974
-
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines
-
He J, Allen JR, Collins VP, Allalunis-Turner MJ, Godbout R, Day Iii RS, James CD. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 1994;54:5804-7.
-
(1994)
Cancer Res
, vol.54
, pp. 5804-5807
-
-
He, J.1
Allen, J.R.2
Collins, V.P.3
Allalunis-Turner, M.J.4
Godbout, R.5
Day, I.R.S.6
James, C.D.7
-
13
-
-
0027454445
-
Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas
-
Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 1993;53:5535-41.
-
(1993)
Cancer Res
, vol.53
, pp. 5535-5541
-
-
Khatib, Z.A.1
Matsushime, H.2
Valentine, M.3
Shapiro, D.N.4
Sherr, C.J.5
Look, A.T.6
-
14
-
-
0032919173
-
Gene amplification and over expression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation
-
An HX, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene amplification and over expression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol. 1999;154:113-8.
-
(1999)
Am J Pathol
, vol.154
, pp. 113-118
-
-
An, H.X.1
Beckmann, M.W.2
Reifenberger, G.3
Bender, H.G.4
Niederacher, D.5
-
15
-
-
0035954134
-
Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix
-
Cheung TH, Yu MMY, Lo KWK, Yim SF, Chung TKH, Wong YF. Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. Cancer Lett. 2001;166:199-206.
-
(2001)
Cancer Lett
, vol.166
, pp. 199-206
-
-
Cheung, T.H.1
Yu, M.M.Y.2
Lo, K.W.K.3
Yim, S.F.4
Chung, T.K.H.5
Wong, Y.F.6
-
16
-
-
0030982897
-
Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA
-
Costello JF, Plass C, Arap W, Chapman VM, Held WA, Berger MS, Su Huang HJ, Cavenee WK. Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res. 1997;57:1250-4.
-
(1997)
Cancer Res
, vol.57
, pp. 1250-1254
-
-
Costello, J.F.1
Plass, C.2
Arap, W.3
Chapman, V.M.4
Held, W.A.5
Berger, M.S.6
Su, H.H.J.7
Cavenee, W.K.8
-
17
-
-
0031963715
-
Differential expression of cyclindependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia
-
Chilosi M, Doglioni C, Yan Z, Lestani M, Menestrina F, Sorio C, Benedetti A, Vinante F, Pizzolo G, Inghirami G. Differential expression of cyclindependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am J Pathol. 1998;152:209-17.
-
(1998)
Am J Pathol
, vol.152
, pp. 209-217
-
-
Chilosi, M.1
Doglioni, C.2
Yan, Z.3
Lestani, M.4
Menestrina, F.5
Sorio, C.6
Benedetti, A.7
Vinante, F.8
Pizzolo, G.9
Inghirami, G.10
-
18
-
-
79960836823
-
Cyclin D as a therapeutic target in cancer
-
Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558-72.
-
(2011)
Nat Rev Cancer
, vol.11
, pp. 558-572
-
-
Musgrove, E.A.1
Caldon, C.E.2
Barraclough, J.3
Stone, A.4
Sutherland, R.L.5
-
20
-
-
0029011539
-
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/ MTS1 in human cancers
-
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/ MTS1 in human cancers. Nat Med. 1995;1:686-92.
-
(1995)
Nat Med
, vol.1
, pp. 686-692
-
-
Merlo, A.1
Herman, J.G.2
Mao, L.3
Lee, D.J.4
Gabrielson, E.5
Burger, P.C.6
Baylin, S.B.7
Sidransky, D.8
-
21
-
-
0028998866
-
Mutations associated with familial melanoma impair p16INK4 function
-
Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D, Dracopoli NC. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet. 1995;10:114-6.
-
(1995)
Nat Genet
, vol.10
, pp. 114-116
-
-
Ranade, K.1
Hussussian, C.J.2
Sikorski, R.S.3
Varmus, H.E.4
Goldstein, A.M.5
Tucker, M.A.6
Serrano, M.7
Hannon, G.J.8
Beach, D.9
Dracopoli, N.C.10
-
22
-
-
0033523992
-
Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations
-
Corcoran MM, Mould SJ, Orchard JA, Ibbotson RE, Chapman RM, Boright AP, Platt C, Tsui LC, Scherer SW, Oscier DG. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18:6271-7.
-
(1999)
Oncogene
, vol.18
, pp. 6271-6277
-
-
Corcoran, M.M.1
Mould, S.J.2
Orchard, J.A.3
Ibbotson, R.E.4
Chapman, R.M.5
Boright, A.P.6
Platt, C.7
Tsui, L.C.8
Scherer, S.W.9
Oscier, D.G.10
-
23
-
-
62849123093
-
Polo-like kinases: Conservation and divergence in their functions and regulation
-
Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol. 2009;10: 265-75.
-
(2009)
Nat Rev Mol Cell Biol
, vol.10
, pp. 265-275
-
-
Archambault, V.1
Glover, D.M.2
-
24
-
-
34948901399
-
Aurora-A: The maker and breaker of spindle poles
-
Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci. 2007;120:2987-96.
-
(2007)
J Cell Sci
, vol.120
, pp. 2987-2996
-
-
Barr, A.R.1
Gergely, F.2
-
25
-
-
33645316142
-
Targeting Polo-like kinase 1 for cancer therapy
-
Strebhardt K, Ullrich A. Targeting Polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006;6:321-30.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 321-330
-
-
Strebhardt, K.1
Ullrich, A.2
-
27
-
-
34447094967
-
A census of mitotic cancer genes: New insights into tumor cell biology and cancer therapy
-
Pérez de Castro I, de Cárcer G, Malumbres M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis. 2007;28:899-912.
-
(2007)
Carcinogenesis
, vol.28
, pp. 899-912
-
-
de Castro, I.P.1
de Cárcer, G.2
Malumbres, M.3
-
28
-
-
0031021648
-
Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: Immunocytochemical and quantitative image analyses
-
Kawamoto H, Koizumi H, Uchikoshi T. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am J Pathol. 1997;150:15-23.
-
(1997)
Am J Pathol
, vol.150
, pp. 15-23
-
-
Kawamoto, H.1
Koizumi, H.2
Uchikoshi, T.3
-
29
-
-
0031040323
-
Overexpression of cyclin B1 in human colorectal cancers
-
Wang A, Yoshimi N, Ino N, Tanaka T, Mori H. Overexpression of cyclin B1 in human colorectal cancers. J Cancer Res Clin Oncol. 1997;123:124-7.
-
(1997)
J Cancer Res Clin Oncol
, vol.123
, pp. 124-127
-
-
Wang, A.1
Yoshimi, N.2
Ino, N.3
Tanaka, T.4
Mori, H.5
-
30
-
-
0029832293
-
Expression of Cell Cycleregulated Proteins in Prostate Cancer
-
Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, Dutta A. Expression of Cell Cycleregulated Proteins in Prostate Cancer. Cancer Res. 1996;56:4159-63.
-
(1996)
Cancer Res
, vol.56
, pp. 4159-4163
-
-
Mashal, R.D.1
Lester, S.2
Corless, C.3
Richie, J.P.4
Chandra, R.5
Propert, K.J.6
Dutta, A.7
-
31
-
-
0033870724
-
Overexpression of Cyclin B1 in Early-Stage Non-Small Cell Lung Cancer and Its Clinical Implication
-
Soria J-C, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L. Overexpression of Cyclin B1 in Early-Stage Non-Small Cell Lung Cancer and Its Clinical Implication. Cancer Res. 2000;60:4000-4.
-
(2000)
Cancer Res
, vol.60
, pp. 4000-4004
-
-
Soria, J.-C.1
Jang, S.J.2
Khuri, F.R.3
Hassan, K.4
Liu, D.5
Hong, W.K.6
Mao, L.7
-
32
-
-
16344361846
-
The Clinical Significance of Aurora-A/STK15/ BTAK Expression in Human Esophageal Squamous Cell Carcinoma
-
Tanaka E, Hashimoto Y, Ito T, Okumura T, Kan T, Watanabe G, Imamura M, Inazawa J, Shimada Y. The Clinical Significance of Aurora-A/STK15/ BTAK Expression in Human Esophageal Squamous Cell Carcinoma. Clin Cancer Res. 2005;11:1827-34.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 1827-1834
-
-
Tanaka, E.1
Hashimoto, Y.2
Ito, T.3
Okumura, T.4
Kan, T.5
Watanabe, G.6
Imamura, M.7
Inazawa, J.8
Shimada, Y.9
-
33
-
-
0033135640
-
Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast
-
Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res. 1999;59:2041-4.
-
(1999)
Cancer Res
, vol.59
, pp. 2041-2044
-
-
Tanaka, T.1
Kimura, M.2
Matsunaga, K.3
Fukada, D.4
Mori, H.5
Okano, Y.6
-
34
-
-
16344376622
-
Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer
-
Hu W, Kavanagh JJ, Deaver M, Johnston DA, Freedman RS, Verschraegen CF, Sen S. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res. 2005;15:49-57.
-
(2005)
Oncol Res
, vol.15
, pp. 49-57
-
-
Hu, W.1
Kavanagh, J.J.2
Deaver, M.3
Johnston, D.A.4
Freedman, R.S.5
Verschraegen, C.F.6
Sen, S.7
-
35
-
-
0032100685
-
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers
-
Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, Chan CS, Novotny M, Slamon DJ, Plowman GD. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998;17:3052-65.
-
(1998)
EMBO J
, vol.17
, pp. 3052-3065
-
-
Bischoff, J.R.1
Anderson, L.2
Zhu, Y.3
Mossie, K.4
Ng, L.5
Souza, B.6
Schryver, B.7
Flanagan, P.8
Clairvoyant, F.9
Ginther, C.10
Chan, C.S.11
Novotny, M.12
Slamon, D.J.13
Plowman, G.D.14
-
36
-
-
7744247124
-
Amplification/overexpression of Aurora-A in human gastric carcinoma: Potential role in differentiated type gastric carcinogenesis
-
Kamada K, Yamada Y, Hirao T, Fujimoto H, Takahama Y, Ueno M, Takayama T, Naito A, Hirao S, Nakajima Y. Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. Oncol Rep. 2004;12:593-9.
-
(2004)
Oncol Rep
, vol.12
, pp. 593-599
-
-
Kamada, K.1
Yamada, Y.2
Hirao, T.3
Fujimoto, H.4
Takahama, Y.5
Ueno, M.6
Takayama, T.7
Naito, A.8
Hirao, S.9
Nakajima, Y.10
-
37
-
-
0033678020
-
Polo-like kinase: A novel marker of proliferation: Correlation with estrogen-receptor expression in human breast cancer
-
Wolf G, Hildenbrand R, Schwar C, Grobholz R, Kaufmann M, Stutte HJ, Strebhardt K, Bleyl U. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol Res Pract. 2000;196:753-9.
-
(2000)
Pathol Res Pract
, vol.196
, pp. 753-759
-
-
Wolf, G.1
Hildenbrand, R.2
Schwar, C.3
Grobholz, R.4
Kaufmann, M.5
Stutte, H.J.6
Strebhardt, K.7
Bleyl, U.8
-
38
-
-
0037648703
-
Pololike kinase 1 (PLK1) is overexpressed in primary colorectal cancers
-
Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S. Pololike kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 2003;94:148-152.
-
(2003)
Cancer Sci
, vol.94
, pp. 148-152
-
-
Takahashi, T.1
Sano, B.2
Nagata, T.3
Kato, H.4
Sugiyama, Y.5
Kunieda, K.6
Kimura, M.7
Okano, Y.8
Saji, S.9
-
39
-
-
0033210869
-
Prognostic significance of Pololike kinase expression in esophageal carcinoma
-
Tokumitsu Y, Mori M, Tanaka S, Akazawa K, Nakano S, Niho Y. Prognostic significance of Pololike kinase expression in esophageal carcinoma. Int J Oncol. 1999;15:687-692.
-
(1999)
Int J Oncol
, vol.15
, pp. 687-692
-
-
Tokumitsu, Y.1
Mori, M.2
Tanaka, S.3
Akazawa, K.4
Nakano, S.5
Niho, Y.6
-
40
-
-
0035839314
-
Polo-like kinase (PLK) expression in endometrial carcinoma
-
Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett. 2001;169:41-9.
-
(2001)
Cancer Lett
, vol.169
, pp. 41-49
-
-
Takai, N.1
Miyazaki, T.2
Fujisawa, K.3
Nasu, K.4
Hamanaka, R.5
Miyakawa, I.6
-
41
-
-
0033564832
-
Prognostic Significance of Pololike Kinase (PLK) Expression in Squamous Cell Carcinomas of the Head and Neck
-
Knecht R, Elez R, Oechler M, Solbach C, Ilberg Cv, Strebhardt K. Prognostic Significance of Pololike Kinase (PLK) Expression in Squamous Cell Carcinomas of the Head and Neck. Cancer Res. 1999;59:2794-2797.
-
(1999)
Cancer Res
, vol.59
, pp. 2794-2797
-
-
Knecht, R.1
Elez, R.2
Oechler, M.3
Solbach, C.4
Ilberg, C.5
Strebhardt, K.6
-
42
-
-
0031051218
-
Prognostic significance of Polo-like kinase (PLK) expression in non-small cell lung cancer
-
Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rubsamen- Waigmann H, Strebhardt K. Prognostic significance of Polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene. 1997;14:543-9.
-
(1997)
Oncogene
, vol.14
, pp. 543-549
-
-
Wolf, G.1
Elez, R.2
Doermer, A.3
Holtrich, U.4
Ackermann, H.5
Stutte, H.J.6
Altmannsberger, H.M.7
Rubsamen-Waigmann, H.8
Strebhardt, K.9
-
43
-
-
0035836079
-
Expression of Polo-like kinase in ovarian cancer is associated with histological grade and clinical stage
-
Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. Expression of Polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett. 2001;164:41-9.
-
(2001)
Cancer Lett
, vol.164
, pp. 41-49
-
-
Takai, N.1
Miyazaki, T.2
Fujisawa, K.3
Nasu, K.4
Hamanaka, R.5
Miyakawa, I.6
-
44
-
-
4444354564
-
Identification of human Polo-like kinase 1 as a potential therapeutic target in pancreatic cancer
-
Gray PJ, Bearss DJ, Han H, Nagle R, Tsao M-S, Dean N, Von Hoff DD. Identification of human Polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther. 2004;3:641-6.
-
(2004)
Mol Cancer Ther
, vol.3
, pp. 641-646
-
-
Gray, P.J.1
Bearss, D.J.2
Han, H.3
Nagle, R.4
Tsao, M.-S.5
Dean, N.6
von Hoff, D.D.7
-
45
-
-
0035990398
-
Expression of Polo-like kinase (PLK1) in thin melanomas: A novel marker of metastatic disease
-
Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of Polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol. 2002;29:354-8.
-
(2002)
J Cutan Pathol
, vol.29
, pp. 354-358
-
-
Kneisel, L.1
Strebhardt, K.2
Bernd, A.3
Wolter, M.4
Binder, A.5
Kaufmann, R.6
-
46
-
-
1942438028
-
Microtubules as a target for anticancer drugs
-
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253-65.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 253-265
-
-
Jordan, M.A.1
Wilson, L.2
-
47
-
-
0033375469
-
Flavopiridol: The first cyclindependent kinase inhibitor in human clinical trials
-
Senderowicz AM. Flavopiridol: the first cyclindependent kinase inhibitor in human clinical trials. Invest New Drugs. 1999;17:313-20.
-
(1999)
Invest New Drugs
, vol.17
, pp. 313-320
-
-
Senderowicz, A.M.1
-
48
-
-
77950837310
-
CDK inhibitors: From the bench to clinical trials
-
Rizzolio F, Tuccinardi T, Caligiuri I, Lucchetti C, Giordano A. CDK inhibitors: from the bench to clinical trials. Curr Drug Targets. 2010;11:279-90.
-
(2010)
Curr Drug Targets
, vol.11
, pp. 279-290
-
-
Rizzolio, F.1
Tuccinardi, T.2
Caligiuri, I.3
Lucchetti, C.4
Giordano, A.5
-
49
-
-
22344456265
-
A structural perspective of CTD function
-
Meinhart A, Kamenski T, Hoeppner S, Baumli S, Cramer P. A structural perspective of CTD function. Genes Dev. 2005;19:1401-15.
-
(2005)
Genes Dev
, vol.19
, pp. 1401-1415
-
-
Meinhart, A.1
Kamenski, T.2
Hoeppner, S.3
Baumli, S.4
Cramer, P.5
-
50
-
-
33846219417
-
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
-
Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker- McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399-404.
-
(2007)
Blood
, vol.109
, pp. 399-404
-
-
Byrd, J.C.1
Lin, T.S.2
Dalton, J.T.3
Wu, D.4
Phelps, M.A.5
Fischer, B.6
Moran, M.7
Blum, K.A.8
Rovin, B.9
Brooker-McEldowney, M.10
Broering, S.11
Schaaf, L.J.12
Johnson, A.J.13
Lucas, D.M.14
Heerema, N.A.15
Lozanski, G.16
Young, D.C.17
Suarez, J.R.18
Colevas, A.D.19
Grever, M.R.20
more..
-
51
-
-
63849246351
-
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
-
Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Brooker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood. 2009;113: 2637-45.
-
(2009)
Blood
, vol.113
, pp. 2637-2645
-
-
Phelps, M.A.1
Lin, T.S.2
Johnson, A.J.3
Hurh, E.4
Rozewski, D.M.5
Farley, K.L.6
Wu, D.7
Blum, K.A.8
Fischer, B.9
Mitchell, S.M.10
Moran, M.E.11
Brooker-McEldowney, M.12
Heerema, N.A.13
Jarjoura, D.14
Schaaf, L.J.15
Byrd, J.C.16
Grever, M.R.17
Dalton, J.T.18
-
52
-
-
9444228344
-
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
-
Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427-38.
-
(2004)
Mol Cancer Ther
, vol.3
, pp. 1427-1438
-
-
Fry, D.W.1
Harvey, P.J.2
Keller, P.R.3
Elliott, W.L.4
Meade, M.5
Trachet, E.6
Albassam, M.7
Zheng, X.8
Leopold, W.R.9
Pryer, N.K.10
Toogood, P.L.11
-
53
-
-
0035907260
-
Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6
-
Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, Dobrusin E, Leopold WR, Fattaey A, Garrett MD. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem. 2001;276:16617-23.
-
(2001)
J Biol Chem
, vol.276
, pp. 16617-16623
-
-
Fry, D.W.1
Bedford, D.C.2
Harvey, P.H.3
Fritsch, A.4
Keller, P.R.5
Wu, Z.6
Dobrusin, E.7
Leopold, W.R.8
Fattaey, A.9
Garrett, M.D.10
-
54
-
-
33748184149
-
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity
-
Marzec M, Kasprzycka M, Lai R, Gladden AB, Wlodarski P, Tomczak E, Nowell P, Deprimo SE, Sadis S, Eck S, Schuster SJ, Diehl JA, Wasik MA. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood. 2006;108:1744-50.
-
(2006)
Blood
, vol.108
, pp. 1744-1750
-
-
Marzec, M.1
Kasprzycka, M.2
Lai, R.3
Gladden, A.B.4
Wlodarski, P.5
Tomczak, E.6
Nowell, P.7
Deprimo, S.E.8
Sadis, S.9
Eck, S.10
Schuster, S.J.11
Diehl, J.A.12
Wasik, M.A.13
-
55
-
-
76049104235
-
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
-
Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.
-
(2009)
Breast Cancer Res
, vol.11
-
-
Finn, R.S.1
Dering, J.2
Conklin, D.3
Kalous, O.4
Cohen, D.J.5
Desai, A.J.6
Ginther, C.7
Atefi, M.8
Chen, I.9
Fowst, C.10
Los, G.11
Slamon, D.J.12
-
56
-
-
77951082119
-
Pharmacologic Inhibition of Cyclin- Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
-
Michaud K, Solomon DA, Oermann E, Kim J-S, Zhong W-Z, Prados MD, Ozawa T, James CD, Waldman T. Pharmacologic Inhibition of Cyclin- Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts. Cancer Res. 2010;70:3228-38.
-
(2010)
Cancer Res
, vol.70
, pp. 3228-3238
-
-
Michaud, K.1
Solomon, D.A.2
Oermann, E.3
Kim, J.-S.4
Zhong, W.-Z.5
Prados, M.D.6
Ozawa, T.7
James, C.D.8
Waldman, T.9
-
57
-
-
79952710710
-
Expression of p16 and Retinoblastoma Determines Response to CDK 4/6 Inhibition in Ovarian Cancer
-
Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, Guorong E, Chalukya M, Wang H-J, Anderson L, Kalli KR, Finn RS, Ginther C, Jones S, Velculescu VE, Riehle D, Cliby WA, Randolph S, Koehler M, Hartmann LC, Slamon DJ. Expression of p16 and Retinoblastoma Determines Response to CDK 4/6 Inhibition in Ovarian Cancer. Clin Cancer Res. 2011;17:1591-1602.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1591-1602
-
-
Konecny, G.E.1
Winterhoff, B.2
Kolarova, T.3
Qi, J.4
Manivong, K.5
Dering, J.6
Guorong, E.7
Chalukya, M.8
Wang, H.-J.9
Anderson, L.10
Kalli, K.R.11
Finn, R.S.12
Ginther, C.13
Jones, S.14
Velculescu, V.E.15
Riehle, D.16
Cliby, W.A.17
Randolph, S.18
Koehler, M.19
Hartmann, L.C.20
Slamon, D.J.21
more..
-
58
-
-
34147127727
-
In vitro antitumor properties of a novel cyclindependent kinase inhibitor, P276-00
-
Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B, Sharma S. In vitro antitumor properties of a novel cyclindependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007;6:918-25.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 918-925
-
-
Joshi, K.S.1
Rathos, M.J.2
Joshi, R.D.3
Sivakumar, M.4
Mascarenhas, M.5
Kamble, S.6
Lal, B.7
Sharma, S.8
-
59
-
-
0020562188
-
Effects of Tamoxifen on Cell Cycle Progression of Synchronous MCF-7 Human Mammary Carcinoma Cells
-
Taylor IW, Hodson PJ, Green MD, Sutherland RL. Effects of Tamoxifen on Cell Cycle Progression of Synchronous MCF-7 Human Mammary Carcinoma Cells. Cancer Res. 1983;43:4007-10.
-
(1983)
Cancer Res
, vol.43
, pp. 4007-4710
-
-
Taylor, I.W.1
Hodson, P.J.2
Green, M.D.3
Sutherland, R.L.4
-
60
-
-
0028799108
-
Gemcitabine: Metabolism, mechanisms of action, and self-potentiation
-
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22:3-10.
-
(1995)
Semin Oncol
, vol.22
, pp. 3-10
-
-
Plunkett, W.1
Huang, P.2
Xu, Y.Z.3
Heinemann, V.4
Grunewald, R.5
Gandhi, V.6
-
61
-
-
33846219417
-
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
-
Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker- McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez J-R, Colevas AD, Grever MR. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399-404.
-
(2007)
Blood
, vol.109
, pp. 399-404
-
-
Byrd, J.C.1
Lin, T.S.2
Dalton, J.T.3
Wu, D.4
Phelps, M.A.5
Fischer, B.6
Moran, M.7
Blum, K.A.8
Rovin, B.9
Brooker-McEldowney, M.10
Broering, S.11
Schaaf, L.J.12
Johnson, A.J.13
Lucas, D.M.14
Heerema, N.A.15
Lozanski, G.16
Young, D.C.17
Suarez, J.-R.18
Colevas, A.D.19
Grever, M.R.20
more..
-
62
-
-
77954929373
-
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
-
Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y, Shapiro GI, Hahn WC, Chin L. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci USA. 2010;107:11501-6.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, pp. 11501-11506
-
-
Wiedemeyer, W.R.1
Dunn, I.F.2
Quayle, S.N.3
Zhang, J.4
Chheda, M.G.5
Dunn, G.P.6
Zhuang, L.7
Rosenbluh, J.8
Chen, S.9
Xiao, Y.10
Shapiro, G.I.11
Hahn, W.C.12
Chin, L.13
-
63
-
-
34548838818
-
Pharmacologic inhibition of CDK4/6: Mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia
-
Wang L, Wang J, Blaser BW, Duchemin A-M, Kusewitt DF, Liu T, Caligiuri MA, Briesewitz R. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood. 2007;110:2075-83.
-
(2007)
Blood
, vol.110
, pp. 2075-2083
-
-
Wang, L.1
Wang, J.2
Blaser, B.W.3
Duchemin, A.-M.4
Kusewitt, D.F.5
Liu, T.6
Caligiuri, M.A.7
Briesewitz, R.8
-
64
-
-
77954757207
-
Therapeutic CDK4/6 inhibition in breast cancer: Key mechanisms of response and failure
-
Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010;29:4018-32.
-
(2010)
Oncogene
, vol.29
, pp. 4018-4032
-
-
Dean, J.L.1
Thangavel, C.2
McClendon, A.K.3
Reed, C.A.4
Knudsen, E.S.5
-
65
-
-
0028172926
-
Absence of p16(ink4) protein is restricted to the subset of lung-cancer lines that retains wildtype RB
-
Otterson GA, Kratzke RA, Coxon A, Kim YW, Kaye FJ. Absence of p16(ink4) protein is restricted to the subset of lung-cancer lines that retains wildtype RB. Oncogene. 1994;9:3375-8.
-
(1994)
Oncogene
, vol.9
, pp. 3375-3378
-
-
Otterson, G.A.1
Kratzke, R.A.2
Coxon, A.3
Kim, Y.W.4
Kaye, F.J.5
-
66
-
-
0028971961
-
Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines
-
Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D, Ewen ME, Rollins BJ. Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 1995;55:6200-9.
-
(1995)
Cancer Res
, vol.55
, pp. 6200-6209
-
-
Shapiro, G.I.1
Park, J.E.2
Edwards, C.D.3
Mao, L.4
Merlo, A.5
Sidransky, D.6
Ewen, M.E.7
Rollins, B.J.8
-
67
-
-
0028911406
-
Increased p16 levels correlate with pRB alterations in human urothelial cells
-
Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRB alterations in human urothelial cells. Cancer Res. 1995;55:493-7.
-
(1995)
Cancer Res
, vol.55
, pp. 493-497
-
-
Yeager, T.1
Stadler, W.2
Belair, C.3
Puthenveettil, J.4
Olopade, O.5
Reznikoff, C.6
-
68
-
-
27144458683
-
Cyclins and CDKS in development and cancer: Lessons from genetically modified mice
-
Santamaria D, Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front Biosci. 2006;11:1164-88.
-
(2006)
Front Biosci
, vol.11
, pp. 1164-1188
-
-
Santamaria, D.1
Ortega, S.2
-
69
-
-
34248671657
-
Mice thrive without Cdk4 and Cdk2
-
Barriere C, Santamaria D, Cerqueira A, Galan J, Martin A, Ortega S, Malumbres M, Dubus P, Barbacid M. Mice thrive without Cdk4 and Cdk2. Mol Oncol. 2007;1:72-83.
-
(2007)
Mol Oncol
, vol.1
, pp. 72-83
-
-
Barriere, C.1
Santamaria, D.2
Cerqueira, A.3
Galan, J.4
Martin, A.5
Ortega, S.6
Malumbres, M.7
Dubus, P.8
Barbacid, M.9
-
70
-
-
0041854279
-
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
-
Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, Barbero JL, Malumbres M, Barbacid M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet. 2003;35:25-31.
-
(2003)
Nat Genet
, vol.35
, pp. 25-31
-
-
Ortega, S.1
Prieto, I.2
Odajima, J.3
Martin, A.4
Dubus, P.5
Sotillo, R.6
Barbero, J.L.7
Malumbres, M.8
Barbacid, M.9
-
71
-
-
0142116249
-
Cdk2 Knockout Mice Are Viable
-
Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 Knockout Mice Are Viable. Current Biol. 2003;13:1775-85.
-
(2003)
Current Biol
, vol.13
, pp. 1775-1785
-
-
Berthet, C.1
Aleem, E.2
Coppola, V.3
Tessarollo, L.4
Kaldis, P.5
-
72
-
-
34547952048
-
Cdk1 is sufficient to drive the mammalian cell cycle
-
Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K, Caceres JF, Dubus P, Malumbres M, Barbacid M. Cdk1 is sufficient to drive the mammalian cell cycle. Nature. 2007;448:811-5.
-
(2007)
Nature
, vol.448
, pp. 811-815
-
-
Santamaria, D.1
Barriere, C.2
Cerqueira, A.3
Hunt, S.4
Tardy, C.5
Newton, K.6
Caceres, J.F.7
Dubus, P.8
Malumbres, M.9
Barbacid, M.10
-
73
-
-
59349089381
-
Phase I dose escalation study of the oral multi-CDK inhibitor PHA- 848125
-
Tibes R, Jimeno A, Von Hoff DD, Walker R, Pacciarini MA, Scaburri A, Fiorentini F, Borad MJ, Jameson GS, Hidalgo M. Phase I dose escalation study of the oral multi-CDK inhibitor PHA- 848125. ASCO Meeting Abstracts. 2008;26:3531.
-
(2008)
ASCO Meeting Abstracts
, vol.26
, pp. 3531
-
-
Tibes, R.1
Jimeno, A.2
von Hoff, D.D.3
Walker, R.4
Pacciarini, M.A.5
Scaburri, A.6
Fiorentini, F.7
Borad, M.J.8
Jameson, G.S.9
Hidalgo, M.10
-
74
-
-
34547650860
-
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: A phase II trial in adults with poor-risk acute myelogenous leukemia
-
Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res. 2007;13:4467-73.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 4467-4473
-
-
Karp, J.E.1
Smith, B.D.2
Levis, M.J.3
Gore, S.D.4
Greer, J.5
Hattenburg, C.6
Briel, J.7
Jones, R.J.8
Wright, J.J.9
Colevas, A.D.10
-
75
-
-
79952443627
-
The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine
-
Walsby E, Lazenby M, Pepper C, Burnett AK. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia. 2011;25:411-9.
-
(2011)
Leukemia
, vol.25
, pp. 411-419
-
-
Walsby, E.1
Lazenby, M.2
Pepper, C.3
Burnett, A.K.4
-
76
-
-
67650038523
-
The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells
-
Kodym E, Kodym R, Reis AE, Habib AA, Story MD, Saha D. The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells. Lung Cancer. 2009;66:37-47.
-
(2009)
Lung Cancer
, vol.66
, pp. 37-47
-
-
Kodym, E.1
Kodym, R.2
Reis, A.E.3
Habib, A.A.4
Story, M.D.5
Saha, D.6
-
77
-
-
48649105786
-
A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model
-
Menu E, Garcia J, Huang X, Di Liberto M, Toogood PL, Chen I, Vanderkerken K, Chen-Kiang S. A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model. Cancer Res. 2008;68:5519-23.
-
(2008)
Cancer Res
, vol.68
, pp. 5519-5523
-
-
Menu, E.1
Garcia, J.2
Huang, X.3
di Liberto, M.4
Toogood, P.L.5
Chen, I.6
Vanderkerken, K.7
Chen-Kiang, S.8
-
78
-
-
33747872306
-
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
-
Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R, Niesvizky R, Cho H, Ely S, Moore MA, Chen-Kiang S. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res. 2006;66:7661-7.
-
(2006)
Cancer Res
, vol.66
, pp. 7661-7667
-
-
Baughn, L.B.1
di Liberto, M.2
Wu, K.3
Toogood, P.L.4
Louie, T.5
Gottschalk, R.6
Niesvizky, R.7
Cho, H.8
Ely, S.9
Moore, M.A.10
Chen-Kiang, S.11
-
79
-
-
79959466807
-
Forced Expression of Cyclin-Dependent Kinase 6 Confers Resistance of Pro-B Acute Lymphocytic Leukemia to Gleevec Treatment
-
Kuo TC, Chavarria-Smith JE, Huang D, Schlissel MS. Forced Expression of Cyclin-Dependent Kinase 6 Confers Resistance of Pro-B Acute Lymphocytic Leukemia to Gleevec Treatment. Mol Cell Biol. 2011;31:2566-76.
-
(2011)
Mol Cell Biol
, vol.31
, pp. 2566-2576
-
-
Kuo, T.C.1
Chavarria-Smith, J.E.2
Huang, D.3
Schlissel, M.S.4
-
80
-
-
84862016904
-
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
-
[Aug 23 Epub ahead of print]
-
Goh KC, Novotny-Diermayr V, Hart S, Ong LC, Loh YK, Cheong A, Tan YC, Hu C, Jayaraman R, William AD, Sun ET, Dymock BW, Ong KH, Ethirajulu K, Burrows F, Wood JM. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia. 2011 [Aug 23 Epub ahead of print].
-
(2011)
Leukemia
-
-
Goh, K.C.1
Novotny-Diermayr, V.2
Hart, S.3
Ong, L.C.4
Loh, Y.K.5
Cheong, A.6
Tan, Y.C.7
Hu, C.8
Jayaraman, R.9
William, A.D.10
Sun, E.T.11
Dymock, B.W.12
Ong, K.H.13
Ethirajulu, K.14
Burrows, F.15
Wood, J.M.16
-
81
-
-
33747128468
-
Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709
-
Siemeister G, Luecking U, Wagner C, Detjen K, Mc Coy C, Bosslet K. Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709. Biomed Pharmacother. 2006;60:269-72.
-
(2006)
Biomed Pharmacother
, vol.60
, pp. 269-272
-
-
Siemeister, G.1
Luecking, U.2
Wagner, C.3
Detjen, K.4
McCoy, C.5
Bosslet, K.6
-
82
-
-
84940363592
-
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours
-
Scott EN, Thomas AL, Molife LR, Ahmed S, Blagden S, Fong PC, Kowal K, McCoy C, Wiesinger H, Steward W, De Bono J. A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2009;64:425-9.
-
(2009)
Cancer Chemother Pharmacol
, vol.64
, pp. 425-429
-
-
Scott, E.N.1
Thomas, A.L.2
Molife, L.R.3
Ahmed, S.4
Blagden, S.5
Fong, P.C.6
Kowal, K.7
McCoy, C.8
Wiesinger, H.9
Steward, W.10
de Bono, J.11
-
83
-
-
70349180350
-
Validated bioanalytical method for the quantification of RGB-286638, a novel multitargeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triplequadrupole mass spectrometry
-
de Bruijn P, Moghaddam-Helmantel IMG, de Jonge MJA, Meyer T, Lam M-H, Verweij J, Wiemer EAC, Loos WJ. Validated bioanalytical method for the quantification of RGB-286638, a novel multitargeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triplequadrupole mass spectrometry. J Pharm Biomed Anal. 2009;50:977-82.
-
(2009)
J Pharm Biomed Anal
, vol.50
, pp. 977-982
-
-
de Bruijn, P.1
Moghaddam-Helmantel, I.M.G.2
de Jonge, M.J.A.3
Meyer, T.4
Lam, M.-H.5
Verweij, J.6
Wiemer, E.A.C.7
Loos, W.J.8
-
84
-
-
25444456359
-
The In vitro and In vivo Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases
-
Emanuel S, Rugg CA, Gruninger RH, Lin R, Fuentes- Pesquera A, Connolly PJ, Wetter SK, Hollister B, Kruger WW, Napier C, Jolliffe L, Middleton SA. The In vitro and In vivo Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases. Cancer Res. 2005;65:9038-46.
-
(2005)
Cancer Res
, vol.65
, pp. 9038-9046
-
-
Emanuel, S.1
Rugg, C.A.2
Gruninger, R.H.3
Lin, R.4
Fuentes-Pesquera, A.5
Connolly, P.J.6
Wetter, S.K.7
Hollister, B.8
Kruger, W.W.9
Napier, C.10
Jolliffe, L.11
Middleton, S.A.12
-
85
-
-
58549089018
-
ATP-noncompetitive inhibitors of CDKcyclin complexes
-
Orzaez M, Gortat A, Mondragon L, Bachs O, Perez- Paya E. ATP-noncompetitive inhibitors of CDKcyclin complexes. Chem Med Chem. 2009;4:19-24.
-
(2009)
Chem Med Chem
, vol.4
, pp. 19-24
-
-
Orzaez, M.1
Gortat, A.2
Mondragon, L.3
Bachs, O.4
Perez-Paya, E.5
-
86
-
-
0033551066
-
Selective killing of transformed cells by cyclin/ cyclin-dependent kinase 2 antagonists
-
Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair KW, Kaelin WG, Jr. Selective killing of transformed cells by cyclin/ cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA. 1999;96:4325-9.
-
(1999)
Proc Natl Acad Sci USA
, vol.96
, pp. 4325-4329
-
-
Chen, Y.N.1
Sharma, S.K.2
Ramsey, T.M.3
Jiang, L.4
Martin, M.S.5
Baker, K.6
Adams, P.D.7
Bair, K.W.8
Kaelin Jr., W.G.9
-
87
-
-
0037374549
-
Selective Cyclin-dependent Kinase 2/Cyclin A Antagonists that Differ from ATP Site Inhibitors Block Tumor Growth
-
Mendoza N, Fong S, Marsters J, Koeppen H, Schwall R, Wickramasinghe D. Selective Cyclin-dependent Kinase 2/Cyclin A Antagonists that Differ from ATP Site Inhibitors Block Tumor Growth. Cancer Res. 2003;63:1020-4.
-
(2003)
Cancer Res
, vol.63
, pp. 1020-1024
-
-
Mendoza, N.1
Fong, S.2
Marsters, J.3
Koeppen, H.4
Schwall, R.5
Wickramasinghe, D.6
-
88
-
-
33845980608
-
Identification of an Hexapeptide That Binds to a Surface Pocket in Cyclin A and Inhibits the Catalytic Activity of the Complex Cyclin-dependent Kinase 2-Cyclin A
-
Canela N, Orzáez M, Fucho R, Mateo F, Gutierrez R, Pineda-Lucena A, Bachs O, Pérez-Payá E. Identification of an Hexapeptide That Binds to a Surface Pocket in Cyclin A and Inhibits the Catalytic Activity of the Complex Cyclin-dependent Kinase 2-Cyclin A. J Biol Chem. 2006;281:35942-53.
-
(2006)
J Biol Chem
, vol.281
, pp. 35942-35953
-
-
Canela, N.1
Orzáez, M.2
Fucho, R.3
Mateo, F.4
Gutierrez, R.5
Pineda-Lucena, A.6
Bachs, O.7
Pérez-Payá, E.8
-
89
-
-
0034721195
-
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
-
Arris CE, Boyle FT, Calvert AH, Curtin NJ, Endicott JA, Garman EF, Gibson AE, Golding BT, Grant S, Griffin RJ, Jewsbury P, Johnson LN, Lawrie AM, Newell DR, Noble ME, Sausville EA, Schultz R, Yu W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem. 2000;43:2797-804.
-
(2000)
J Med Chem
, vol.43
, pp. 2797-2804
-
-
Arris, C.E.1
Boyle, F.T.2
Calvert, A.H.3
Curtin, N.J.4
Endicott, J.A.5
Garman, E.F.6
Gibson, A.E.7
Golding, B.T.8
Grant, S.9
Griffin, R.J.10
Jewsbury, P.11
Johnson, L.N.12
Lawrie, A.M.13
Newell, D.R.14
Noble, M.E.15
Sausville, E.A.16
Schultz, R.17
Yu, W.18
-
90
-
-
33947498211
-
A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo
-
Bagella L, Sun A, Tonini T, Abbadessa G, Cottone G, Paggi MG, De Luca A, Claudio PP, Giordano A. A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene. 2007;26:1829-39.
-
(2007)
Oncogene
, vol.26
, pp. 1829-1839
-
-
Bagella, L.1
Sun, A.2
Tonini, T.3
Abbadessa, G.4
Cottone, G.5
Paggi, M.G.6
de Luca, A.7
Claudio, P.P.8
Giordano, A.9
-
91
-
-
28044454553
-
Current strategies for the development of peptide-based anti-cancer therapeutics
-
Borghouts C, Kunz C, Groner B. Current strategies for the development of peptide-based anti-cancer therapeutics. J Pept Sci. 2005;11:713-26.
-
(2005)
J Pept Sci
, vol.11
, pp. 713-726
-
-
Borghouts, C.1
Kunz, C.2
Groner, B.3
-
92
-
-
70349383205
-
3rd. Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides
-
Raucher D, Moktan S, Massodi I, Bidwell GL, 3rd. Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin Drug Deliv. 2009;6:1049-64.
-
(2009)
Expert Opin Drug Deliv
, vol.6
, pp. 1049-1064
-
-
Raucher, D.1
Moktan, S.2
Massodi, I.3
Bidwell, G.L.4
-
93
-
-
79959952060
-
Somatic variation and cancer: Therapies lost in the mix
-
Biankin AV, Hudson TJ. Somatic variation and cancer: therapies lost in the mix. Hum Genet. 2011;130:79-91.
-
(2011)
Hum Genet
, vol.130
, pp. 79-91
-
-
Biankin, A.V.1
Hudson, T.J.2
-
94
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
-
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-97.
-
(2010)
Lancet
, vol.376
, pp. 687-697
-
-
Bang, Y.J.1
van Cutsem, E.2
Feyereislova, A.3
Chung, H.C.4
Shen, L.5
Sawaki, A.6
Lordick, F.7
Ohtsu, A.8
Omuro, Y.9
Satoh, T.10
Aprile, G.11
Kulikov, E.12
Hill, J.13
Lehle, M.14
Ruschoff, J.15
Kang, Y.K.16
-
95
-
-
10344236486
-
Aurora-kinase inhibitors as anticancer agents
-
Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 2004;4:927-36.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 927-936
-
-
Keen, N.1
Taylor, S.2
-
97
-
-
39149089275
-
Polo and Aurora kinases: Lessons derived from chemical biology
-
Taylor S, Peters JM. Polo and Aurora kinases: lessons derived from chemical biology. Curr Opin Cell Biol. 2008;20:77-84.
-
(2008)
Curr Opin Cell Biol
, vol.20
, pp. 77-84
-
-
Taylor, S.1
Peters, J.M.2
-
98
-
-
0032213515
-
Multinuclearity and Increased Ploidy Caused by Overexpression of the Auroraand Ipl1-like Midbody-associated Protein Mitotic Kinase in Human Cancer Cells
-
Tatsuka M, Katayama H, Ota T, Tanaka T, Odashima S, Suzuki F, Terada Y. Multinuclearity and Increased Ploidy Caused by Overexpression of the Auroraand Ipl1-like Midbody-associated Protein Mitotic Kinase in Human Cancer Cells. Cancer Res. 1998;58:4811-6.
-
(1998)
Cancer Res
, vol.58
, pp. 4811-4816
-
-
Tatsuka, M.1
Katayama, H.2
Ota, T.3
Tanaka, T.4
Odashima, S.5
Suzuki, F.6
Terada, Y.7
-
99
-
-
27744511262
-
Aurora-B//AIM-1 kinase activity is involved in Ras-mediated cell transformation
-
Kanda A, Kawai H, Suto S, Kitajima S, Sato S, Takata T, Tatsuka M. Aurora-B//AIM-1 kinase activity is involved in Ras-mediated cell transformation. Oncogene. 2005;24:7266-72.
-
(2005)
Oncogene
, vol.24
, pp. 7266-7272
-
-
Kanda, A.1
Kawai, H.2
Suto, S.3
Kitajima, S.4
Sato, S.5
Takata, T.6
Tatsuka, M.7
-
100
-
-
0037105758
-
Increased Mitotic Phosphorylation of Histone H3 Attributable to AIM-1/Aurora-B Overexpression Contributes to Chromosome Number Instability
-
Ota T, Suto S, Katayama H, Han Z-B, Suzuki F, Maeda M, Tanino M, Terada Y, Tatsuka M. Increased Mitotic Phosphorylation of Histone H3 Attributable to AIM-1/Aurora-B Overexpression Contributes to Chromosome Number Instability. Cancer Res. 2002;62:5168-77.
-
(2002)
Cancer Res
, vol.62
, pp. 5168-5177
-
-
Ota, T.1
Suto, S.2
Katayama, H.3
Han, Z.-B.4
Suzuki, F.5
Maeda, M.6
Tanino, M.7
Terada, Y.8
Tatsuka, M.9
-
101
-
-
79956223049
-
Aurora kinase inhibitor patents and agents in clinical testing: An update (2009-10)
-
Cheung CH, Coumar MS, Chang JY, Hsieh HP. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Pat. 2011;21:857-84.
-
(2011)
Expert Opin Ther Pat
, vol.21
, pp. 857-884
-
-
Cheung, C.H.1
Coumar, M.S.2
Chang, J.Y.3
Hsieh, H.P.4
-
102
-
-
82955217793
-
Phase I/II study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
-
Oct 5 Epub ahead of print
-
Lowenberg B, Muus P, Ossenkoppele G, Rousselot P, Cahn JY, Ifrah N, Martinelli G, Amadori S, Berman E, Sonneveld P, Jongen-Lavrencic M, Rigaudeau S, Stockman P, Goudie A, Faderl S, Jabbour E, Kantarjian H. Phase I/II study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood. 2011 [Oct 5 Epub ahead of print].
-
(2011)
Blood
-
-
Lowenberg, B.1
Muus, P.2
Ossenkoppele, G.3
Rousselot, P.4
Cahn, J.Y.5
Ifrah, N.6
Martinelli, G.7
Amadori, S.8
Berman, E.9
Sonneveld, P.10
Jongen-Lavrencic, M.11
Rigaudeau, S.12
Stockman, P.13
Goudie, A.14
Faderl, S.15
Jabbour, E.16
Kantarjian, H.17
-
104
-
-
33745234790
-
Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo
-
Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, Strebhardt K. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res. 2006;66:5836-46.
-
(2006)
Cancer Res
, vol.66
, pp. 5836-5846
-
-
Spankuch, B.1
Heim, S.2
Kurunci-Csacsko, E.3
Lindenau, C.4
Yuan, J.5
Kaufmann, M.6
Strebhardt, K.7
-
105
-
-
33644767315
-
Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion
-
Liu X, Lei M, Erikson RL. Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion. Mol Cell Biol. 2006;26:2093-108.
-
(2006)
Mol Cell Biol
, vol.26
, pp. 2093-2108
-
-
Liu, X.1
Lei, M.2
Erikson, R.L.3
-
106
-
-
79959696118
-
PLK1 as an oncology target: Current status and future potential
-
McInnes C, Wyatt MD. PLK1 as an oncology target: current status and future potential. Drug Discov Today. 2011;16:619-25.
-
(2011)
Drug Discov Today
, vol.16
, pp. 619-625
-
-
McInnes, C.1
Wyatt, M.D.2
-
107
-
-
17144385867
-
Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: An atypical tyrosine kinase with a key role in CDK1 regulation
-
Squire CJ, Dickson JM, Ivanovic I, Baker EN. Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. Structure. 2005;13:541-50.
-
(2005)
Structure
, vol.13
, pp. 541-550
-
-
Squire, C.J.1
Dickson, J.M.2
Ivanovic, I.3
Baker, E.N.4
-
108
-
-
80052491760
-
MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
-
Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE. MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells. Clin Cancer Res. 2011;17:5638-48.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5638-5648
-
-
Bridges, K.A.1
Hirai, H.2
Buser, C.A.3
Brooks, C.4
Liu, H.5
Buchholz, T.A.6
Molkentine, J.M.7
Mason, K.A.8
Meyn, R.E.9
-
109
-
-
77953711939
-
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNAdamaging agents, including 5-fluorouracil
-
Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T, Mizuarai S, Iwasawa Y, Kotani H. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNAdamaging agents, including 5-fluorouracil. Cancer Biol Ther. 2010;9:514-22.
-
(2010)
Cancer Biol Ther
, vol.9
, pp. 514-522
-
-
Hirai, H.1
Arai, T.2
Okada, M.3
Nishibata, T.4
Kobayashi, M.5
Sakai, N.6
Imagaki, K.7
Ohtani, J.8
Sakai, T.9
Yoshizumi, T.10
Mizuarai, S.11
Iwasawa, Y.12
Kotani, H.13
-
110
-
-
13844252061
-
The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment
-
Dai J, Sultan S, Taylor SS, Higgins JM. The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment. Genes Dev. 2005;19:472-88.
-
(2005)
Genes Dev
, vol.19
, pp. 472-488
-
-
Dai, J.1
Sultan, S.2
Taylor, S.S.3
Higgins, J.M.4
-
111
-
-
84858339528
-
Antitumor activity of a smallmolecule inhibitor of the histone kinase Haspin
-
Aug 1 Epub ahead of print
-
Huertas D, Soler M, Moreto J, Villanueva A, Martinez A, Vidal A, Charlton M, Moffat D, Patel S, McDermott J, Owen J, Brotherton D, Krige D, Cuthill S, Esteller M. Antitumor activity of a smallmolecule inhibitor of the histone kinase Haspin. Oncogene. 2011 [Aug 1 Epub ahead of print].
-
(2011)
Oncogene
-
-
Huertas, D.1
Soler, M.2
Moreto, J.3
Villanueva, A.4
Martinez, A.5
Vidal, A.6
Charlton, M.7
Moffat, D.8
Patel, S.9
McDermott, J.10
Owen, J.11
Brotherton, D.12
Krige, D.13
Cuthill, S.14
Esteller, M.15
-
112
-
-
0015223149
-
Genetic control of the cell division cycle in yeast. II. Genes controlling DNA replication and its initiation
-
Hartwell LH. Genetic control of the cell division cycle in yeast. II. Genes controlling DNA replication and its initiation. J Mol Biol. 1971;59:183-94.
-
(1971)
J Mol Biol
, vol.59
, pp. 183-194
-
-
Hartwell, L.H.1
-
113
-
-
50949102890
-
Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation
-
Bonte D, Lindvall C, Liu H, Dykema K, Furge K, Weinreich M. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia. 2008; 10:920-31.
-
(2008)
Neoplasia
, vol.10
, pp. 920-931
-
-
Bonte, D.1
Lindvall, C.2
Liu, H.3
Dykema, K.4
Furge, K.5
Weinreich, M.6
-
114
-
-
77956713455
-
Targeting cell division cycle 7 kinase: A new approach for cancer therapy
-
Montagnoli A, Moll J, Colotta F. Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Clin Cancer Res. 2010;16:4503-8.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4503-4508
-
-
Montagnoli, A.1
Moll, J.2
Colotta, F.3
-
115
-
-
4944256913
-
Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells
-
Montagnoli A, Tenca P, Sola F, Carpani D, Brotherton D, Albanese C, Santocanale C. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Res. 2004;64:7110-6.
-
(2004)
Cancer Res
, vol.64
, pp. 7110-7116
-
-
Montagnoli, A.1
Tenca, P.2
Sola, F.3
Carpani, D.4
Brotherton, D.5
Albanese, C.6
Santocanale, C.7
|